Company: CRNX
Filing Date: 2025-04-23
Form Type: DEFA14A
Source: 0000950170-25-057462
Chunk: 1

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEFA14A
Chunk 1
---
 by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 30, 2025. Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 11, 2025 For Stockholders of record as of April 14, 2025 To order paper materials, use one of the following methods. Internet: www.investorelections.com/CRNX Call: 1-866-648-8133 Email: paper@investorelections.com * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved

Crinetics Crinetics Pharmaceuticals, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ALL THE DIRECTORS ON PROPOSAL 1 AND FOR ON PROPOSALS 2 AND 3 PROPOSAL 1. To elect three directors to serve as Class I directors for a three-year term to expire at the 2028 annual meeting of stockholders; 1.01 Matthew K. Fust 1.02 R. Scott Struthers, Ph.D. 1.03 Rogério Vivaldi Coelho, M.D. 2. To consider and vote upon the ratification of the selection of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2025; 3. To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; 4. To transact such other business as may be properly brought before the annual meeting or any adjournment or postponement thereof.

Crinetics C/O TABULATOR,